Condition: Advanced or Metastatic Colorectal Cancer · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) and to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| O Neal Comprehensive Cancer Center at UAB | Birmingham, Alabama, United States | Completed |
| University of Southern California | Los Angeles, California, United States | Completed |
| University of California, Los Angeles UCLA | Los Angeles, California, United States | Recruiting |
| Georgetown University Hospital | Washington D.C., District of Columbia, United States | Completed |
| H Lee Moffitt Cancer Center | Tampa, Florida, United States | Completed |
| University of Maryland School of Medicine | Baltimore, Maryland, United States | Completed |
| University of Michigan Health System | Ann Arbor, Michigan, United States | Recruiting |
| Start Midwest | Grand Rapids, Michigan, United States | Completed |
| Hattiesburg Clinic | Hattiesburg, Mississippi, United States | Recruiting |
| NYU Langone Long Island Clinical Research Associates | New York, New York, United States | Recruiting |
| Herbert Irving Comprehensive Cancer Center Columbia University Medical Center | New York, New York, United States | Recruiting |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Completed |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05379595